$BNTX (-3,32 %) I increased my BioNTech position a little yesterday. Another position went into each of the two children's portfolios.

Certainly a company where you still need a little patience.

In addition to the development of coronavirus vaccines, the focus at Biontech is now on oncology research. The first cancer drug is due to be launched on the market in 2026.

By 2030, the company aims to have achieved ten approvals in various cancer indications.